U.S. FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA's Drug Safety and Risk Management Advisory Committee will not recommend that the agency approve Daiichi Sankyo's U.S. subsidiary Luitpold's Injectafer for first-line treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, the panel decided at its Feb. 1 meeting